A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb
Contact:
NCT Number:
Protocol:
AAAT0876
Study Status:
Active/Enrolling
Population:
Adult
Phase:
III
The purpose of the study is to determine if the drug, CAEL-101 in combination with plasma cell treatment improves overall survival for patients who are diagnosed with stage 3b of AL amyloidosis. Patients who participate in this study will receive CAEL-101 as well as plasma cell treatment or Placebo as well as plasma cell treatment to compare the effects.
Are you Eligible? (Inclusion Criteria)
- Are you 18 years of age or older?
- Are you diagnosed with stage 3b of AL amyloidosis?
- Have you not receive treatment for your disease?
Specialty Area(s)
Multiple Myeloma/Amyloidosis, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
